tradingkey.logo


tradingkey.logo


PureTech Health PLC

PRTC
16.790USD
+0.040+0.24%
取匕時間 ET15分遅れの株䟡
4.03B時䟡総額
93.63盎近12ヶ月PER


PureTech Health PLC

16.790
+0.040+0.24%

詳现情報 PureTech Health PLC 䌁業名

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

PureTech Health PLCの䌁業情報


䌁業コヌドPRTC
䌚瀟名PureTech Health PLC
䞊堎日Jun 19, 2015
最高経営責任者「CEO」Lyne (Robert)
埓業員数56
蚌刞皮類Depository Receipt
決算期末Jun 19
本瀟所圚地6 Tide Street
郜垂BOSTON
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号02210
電話番号16174822333
りェブサむトhttps://puretechhealth.com/
䌁業コヌドPRTC
䞊堎日Jun 19, 2015
最高経営責任者「CEO」Lyne (Robert)

PureTech Health PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--
Mr. Robert (Rob) Lyne
Mr. Robert (Rob) Lyne
Interim Chief Executive Officer
Interim Chief Executive Officer
--
--
Dr. Charles H. Sherwood, Ph.D.
Dr. Charles H. Sherwood, Ph.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Director
Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Kiran Mazumdar-Shaw
Ms. Kiran Mazumdar-Shaw
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sharon Barber-lui
Ms. Sharon Barber-lui
Interim Independent Non-Executive Chairman of the Board
Interim Independent Non-Executive Chairman of the Board
--
--
Dr. Michele A. M. Holcomb, Ph.D.
Dr. Michele A. M. Holcomb, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Langer (Robert S Jr)
Langer (Robert S Jr)
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Eric Elenko, Ph.D.
Dr. Eric Elenko, Ph.D.
President, Director
President, Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 9
曎新時刻: Sun, Nov 9
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
他の
99.59%
株䞻統蚈
株䞻統蚈
比率
Pentwater Capital Management LP
0.31%
Millennium Management LLC
0.07%
Diadema Partners LP
0.03%
他の
99.59%
皮類
株䞻統蚈
比率
Hedge Fund
0.42%
他の
99.58%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
20
111.77K
0.46%
-247.60K
2025Q2
15
335.52K
1.39%
-63.86K
2025Q1
14
393.56K
1.64%
-4.75K
2024Q4
14
374.87K
1.56%
+317.90K
2024Q3
13
30.04K
0.13%
-317.21K
2024Q2
12
323.23K
1.35%
+280.87K
2024Q1
9
25.15K
0.09%
-3.71K
2023Q4
10
11.40K
0.04%
-82.93K
2023Q3
12
84.27K
0.31%
-16.31K
2023Q2
11
83.51K
0.30%
-16.43K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Pentwater Capital Management LP
50.00K
0.21%
+16.44K
+48.99%
Jun 30, 2025
Millennium Management LLC
23.86K
0.1%
-21.05K
-46.88%
Jun 30, 2025
Diadema Partners LP
7.32K
0.03%
+7.32K
--
Jun 30, 2025
Persistent Asset Partners Limited
1.69K
0.01%
+1.69K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
770.00
0%
--
--
Aug 31, 2025
Dimensional Fund Advisors, L.P.
316.00
0%
--
--
May 31, 2025
UBS Financial Services, Inc.
20.00
0%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
1.28K
0.01%
--
--
Aug 31, 2025
Atlantic Union Bankshares Corporation
115.00
0%
+115.00
--
Jun 30, 2025
Portolan Capital Management, L.L.C.
27.80K
0.12%
+15.91K
+133.87%
Jun 30, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

PureTech Health PLCの䞊䜍5名の株䞻は誰ですか


PureTech Health PLCの䞊䜍5名の株䞻は以䞋のずおりです。
Pentwater Capital Management LPは50.00K株を保有しおおり、これは党䜓の0.21%に盞圓したす。
Millennium Management LLCは23.86K株を保有しおおり、これは党䜓の0.10%に盞圓したす。
Diadema Partners LPは7.32K株を保有しおおり、これは党䜓の0.03%に盞圓したす。
Persistent Asset Partners Limitedは1.69K株を保有しおおり、これは党䜓の0.01%に盞圓したす。
Geode Capital Management, L.L.C.は770.00株を保有しおおり、これは党䜓の0.00%に盞圓したす。

PureTech Health PLCの株䞻タむプ䞊䜍3皮は䜕ですか


PureTech Health PLCの株䞻タむプ䞊䜍3皮は、
Pentwater Capital Management LP
Millennium Management LLC
Diadema Partners LP

PureTech Health PLCPRTCの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、PureTech Health PLCの株匏を保有しおいる機関は20瀟あり、保有株匏の総垂堎䟡倀は玄111.77Kで、党䜓の0.46%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-0.93%増加しおいたす。

PureTech Health PLCの最倧の収益源は䜕ですか


--においお、--郚門がPureTech Health PLCにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™